- Home
- GEVO vs RGNX Comparison
GEVO vs RGNX Comparison
Compare GEVO & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- RGNX
- Stock Information
- Founded
- GEVO 2005
- RGNX 2008
- Country
- GEVO United States
- RGNX United States
- Employees
- GEVO N/A
- RGNX N/A
- Industry
- GEVO Major Chemicals
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GEVO Industrials
- RGNX Health Care
- Exchange
- GEVO Nasdaq
- RGNX Nasdaq
- Market Cap
- GEVO 354.6M
- RGNX 424.8M
- IPO Year
- GEVO 2011
- RGNX 2015
- Fundamental
- Price
- GEVO $1.47
- RGNX $8.96
- Analyst Decision
- GEVO Buy
- RGNX Strong Buy
- Analyst Count
- GEVO 2
- RGNX 8
- Target Price
- GEVO $7.58
- RGNX $31.75
- AVG Volume (30 Days)
- GEVO 4.9M
- RGNX 603.1K
- Earning Date
- GEVO 08-11-2025
- RGNX 08-08-2025
- Dividend Yield
- GEVO N/A
- RGNX N/A
- EPS Growth
- GEVO N/A
- RGNX N/A
- EPS
- GEVO N/A
- RGNX N/A
- Revenue
- GEVO $42,034,000.00
- RGNX $156,718,000.00
- Revenue This Year
- GEVO $1,022.79
- RGNX $327.08
- Revenue Next Year
- GEVO $12.26
- RGNX N/A
- P/E Ratio
- GEVO N/A
- RGNX N/A
- Revenue Growth
- GEVO 145.38
- RGNX 80.70
- 52 Week Low
- GEVO $0.48
- RGNX $5.04
- 52 Week High
- GEVO $3.39
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- GEVO 52.84
- RGNX 52.82
- Support Level
- GEVO $1.43
- RGNX $8.14
- Resistance Level
- GEVO $1.58
- RGNX $8.94
- Average True Range (ATR)
- GEVO 0.09
- RGNX 0.49
- MACD
- GEVO -0.01
- RGNX 0.07
- Stochastic Oscillator
- GEVO 36.36
- RGNX 72.57
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.